<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(1)</volume><submitter>Kim WJ</submitter><funding>Chong Kun Dang Bio Co. Ltd</funding><pubmed_abstract>The gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of &lt;i>Bifidobacterium longum&lt;/i> NBM7-1 (CKD1) with anti-diabetic medicines, Lobeglitazone&lt;sup>Ⓡ&lt;/sup> (LO), Sitagliptin&lt;sup>Ⓡ&lt;/sup> (SI), and Metformin&lt;sup>Ⓡ&lt;/sup> (Met), to alleviate hyperglycemia in a diabetic mouse model. CKD1 effectively mitigated insulin resistance, hepatic steatosis, and enhanced pancreatic β-cell function, as well as fortifying gut-tight junction integrity. In the same way, SI-CKD1 and Met- CKD1 synergistically improved insulin sensitivity and prevented hepatic steatosis, as evidenced by the modulation of key genes associated with insulin signaling, β-oxidation, gluconeogenesis, ad</pubmed_abstract><journal>Gut microbes</journal><pagination>2319889</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10896159</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&lt;i>B. longum&lt;/i> CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice.</pubmed_title><pmcid>PMC10896159</pmcid><pubmed_authors>Kim WJ</pubmed_authors><pubmed_authors>Lee C</pubmed_authors><pubmed_authors>Kim TY</pubmed_authors><pubmed_authors>Kim H</pubmed_authors><pubmed_authors>Han G</pubmed_authors><pubmed_authors>Kim K</pubmed_authors><pubmed_authors>Huh CS</pubmed_authors><pubmed_authors>Choi Y</pubmed_authors><pubmed_authors>Shin CH</pubmed_authors><pubmed_authors>Park SY</pubmed_authors><pubmed_authors>Kil BJ</pubmed_authors><pubmed_authors>Kim M</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>B. longum&lt;/i> CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice.</name><description>The gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of &lt;i>Bifidobacterium longum&lt;/i> NBM7-1 (CKD1) with anti-diabetic medicines, Lobeglitazone&lt;sup>Ⓡ&lt;/sup> (LO), Sitagliptin&lt;sup>Ⓡ&lt;/sup> (SI), and Metformin&lt;sup>Ⓡ&lt;/sup> (Met), to alleviate hyperglycemia in a diabetic mouse model. CKD1 effectively mitigated insulin resistance, hepatic steatosis, and enhanced pancreatic β-cell function, as well as fortifying gut-tight junction integrity. In the same way, SI-CKD1 and Met- CKD1 synergistically improved insulin sensitivity and prevented hepatic steatosis, as evidenced by the modulation of key genes associated with insulin signaling, β-oxidation, gluconeogenesis, ad</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan-Dec</publication><modification>2026-05-09T03:10:34.409Z</modification><creation>2025-05-29T21:39:01.639Z</creation></dates><accession>S-EPMC10896159</accession><cross_references><pubmed>38391178</pubmed><doi>10.1080/19490976.2024.2319889</doi></cross_references></HashMap>